212 related articles for article (PubMed ID: 9673398)
1. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
Pihie AH; Stanslas J; Din LB
Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398
[TBL] [Abstract][Full Text] [Related]
2. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity.
Hawariah A; Stanslas J
Anticancer Res; 1998; 18(6A):4383-6. PubMed ID: 9891496
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
[TBL] [Abstract][Full Text] [Related]
4. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
6. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
Liu ZJ; Zhu BT
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine.
Strobl JS; Kirkwood KL; Lantz TK; Lewine MA; Peterson VA; Worley JF
Cancer Res; 1990 Sep; 50(17):5399-405. PubMed ID: 2386945
[TBL] [Abstract][Full Text] [Related]
8. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
10. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.
Reiner GC; Katzenellenbogen BS
Cancer Res; 1986 Mar; 46(3):1124-31. PubMed ID: 3943090
[TBL] [Abstract][Full Text] [Related]
11. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.
Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL
Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
Strobl JS; Peterson VA
J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines.
Otto AM; Faderl M; Schönenberger H
Cancer Res; 1991 Jun; 51(12):3217-23. PubMed ID: 2039997
[TBL] [Abstract][Full Text] [Related]
14. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
16. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
17. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA.
Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Chan VS; Ho GH
Clin Cancer Res; 1999 Feb; 5(2):395-403. PubMed ID: 10037189
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
19. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
20. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
